Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07414784
PHASE1
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.
Official title: A Phase 1 Drug-Drug Interaction Study of ABBV-295, Levonorgestrel, and Ethinyl Estradiol in Healthy Adult Female Subjects With Overweight or Obesity
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-02-11
Completion Date
2026-07
Last Updated
2026-02-17
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ABBV-295
Subcutaneous Injections
DRUG
Levonorgestrel/Ethinyl Estradiol
Oral Tablet
Locations (1)
ACPRU
Grayslake, Illinois, United States